Will return to India soon, says Adar Poonawalla

Poonawalla had told The Times in an interview about receiving aggressive calls from some of the most powerful people in India, demanding supplies of Covishield

May 02, 2021 08:48 am | Updated November 30, 2021 06:40 pm IST - Mumbai

Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India

Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India

Serum Institute of India CEO Adar Poonawalla has said he will return to India from London in a few days.

Poonawalla made the announcement soon after he spoke out about the pressures he was under over the production of COVID-19 vaccines to meet the ever-increasing demand in India as the country battles through a devastating second wave of the coronavirus pandemic.

"Had an excellent meeting with all our partners & stakeholders in the U.K. Meanwhile, pleased to state that COVISHIELD's production is in full swing in Pune. I look forward to reviewing operations upon my return in a few days," Poonawalla said in a midnight tweet.

In his first comments since he was provided with 'Y' category security by the Indian government earlier this week, Poonawalla had told The Times in an interview about receiving aggressive calls from some of the most powerful people in India, demanding supplies of Covishield — the Oxford/AstraZeneca COVID-19 vaccine that the Serum Institute is producing in India.

That pressure was largely behind his decision to fly into London to be with his wife and children, the 40-year-old entrepreneur had said in the interview on Saturday.

According to Indian government officials, the protection to Poonawalla has been given in view of "potential threats" to him. Armed commandos of the Central Reserve Police Force (CRPF) will be with him every time he travels to any part of the country, they said and added that the 'Y' security cover will entail a posse of about 4-5 armed commandos.

 

According to the newspaper, by the time the Oxford/AstraZeneca vaccine was approved in January this year, the Serum Institute of India (SII) had increased its annual production capacity from 1.5 to 2.5 billion doses at a cost of $800 million, and stockpiled 50 million doses of Covishield. The company began exporting to 68 countries, including Britain, as India seemed to have been over the worse, until the situation worsened in recent weeks.

India's daily coronavirus tally crossed the grim milestone of four lakh, while the death toll rose to 2,11,853 with 3,523 fresh fatalities, according to date updated by the Union Health Ministry on Saturday. The infection tally rose to 1,91,64,969 with 4,01,993 new cases, while the active cases crossed the 32-lakh mark, the data updated at 8 am on Saturday showed.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.